BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

...setting. At least a dozen companies have anti-tau therapies in clinical testing. AbbVie’s tau mAb ABBV-8E12...
BioCentury | Jul 16, 2020
Product Development

AC Immune’s biggest stock move this year likely to come from tau mAb

...with a primary completion date of March 26, 2024, and a Phase II trial of ABBV-8E12...
BioCentury | Feb 28, 2020
Deals

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

...In June, AbbVie Inc. (NYSE:ABBV) discontinued a Phase II trial of its tau-targeting mAb ABBV-8E12...
BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...tau-targeting mAb ABBV-8E12 to treat PSP while continuing the candidate’s development in AD. Gosuranemab and ABBV-8E12...
...Alzheimer’s disease; they are the only two to reach Phase II for PSP. AbbVie holds ABBV-8E12’s...
BioCentury | Jul 26, 2019
Company News

AbbVie’s 2Q previews future growth drivers

...on Steeper Humira Erosion" ). Separately, AbbVie said it discontinued a Phase II trial of ABBV-8E12...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

...trials are LY3303560 from Lilly, BIIB092 from Biogen Inc. and partner Bristol-Myers Squibb Co., and ABBV-8E12...
...TauRx Pharmaceuticals Ltd., Singapore Targets Tau (MAPT; FTDP-17) - Microtubule-associated protein tau Selina Koch, Senior Editor ABBV-8E12, C2N-8E12 Anti...
BioCentury | Jul 27, 2018
Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
BioCentury | Feb 23, 2018
Company News

Voyager, AbbVie to develop anti-tau gene therapies

...AD. J&J could not be reached for comment on Tuesday regarding specific targets. AbbVie's IV ABBV-8E12...
...recombinant mAb that targets tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12...
BioCentury | Feb 20, 2018
Company News

Voyager, AbbVie partner for AD gene therapies

...for comment on Tuesday regarding specific targets (see BioCentury Extra, Jan. 5) . AbbVie's IV ABBV-8E12...
...recombinant mAb that targets tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12...
BioCentury | May 25, 2017
Company News

Merck obtains rights to Teijin's tau candidate

...Jan. 12, 2015) . In January, AbbVie Inc. (NYSE:ABBV) began a Phase II study of ABBV-8E12...
...whose rights it obtained from Bristol-Myers Squibb (NYSE:BMY) (see BioCentury Extra, April 13) . Jaime De Leon ABBV-8E12 ACI-35 C2N-8E12 LMTX Tau...
Items per page:
1 - 10 of 17